Inflammation in Parkinson’s disease: Role of glucocorticoids

Frontiers in Neuroanatomy

Volumn 9, Issue APR, 2015, Pages

  Herrero, María Trinidad ^a   Estrada, Cristina ^a   Maatouk, Layal ^b   Vyas, Sheela ^b  

^a UNIVERSITY OF MURCIA   (Spain)

^b CNRS   (France)

Author keywords

Glucocorticoid receptor; Microglia; Neurodegeneration; Neuroinflammation; Parkinson s disease (PD)

Indexed keywords

ALPHA SYNUCLEIN; CORTICOTROPIN; CORTISONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HEAT SHOCK PROTEIN; HISTONE DEACETYLASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOPHILIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEUCINE RICH REPEAT KINASE 2; MINERALOCORTICOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOLIPASE A2; PROSTAGLANDIN E2; RANTES; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE 1; SYNAPTOTAGMIN I; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY LABELING; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; CELL ACTIVATION; CELL INFILTRATION; ENVIRONMENTAL FACTOR; GENE MUTATION; HUMAN; INNATE IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROGLIA; NERVE CELL DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE;

EID: 84930508415     PISSN: 16625129     EISSN: 16625129     Source Type: Journal    
DOI: 10.3389/fnana.2015.00032     Document Type: Review

References (126)

1. Abdullah, R., Basak, I., Patil, K. S., Alves, G., Larsen, J. P., and Møll, S. G. (2014). Parkinson's disease and age: the obvious but largely unexplored link. Exp. Gerontol. doi: 10. 1016/j. exger. 2014. 09. 014. [Epub ahead of print].
2. Ahmed, I., Tamouza, R., Delord, M., Krishnamoorthy, R., Tzourio, C., Mulot, C., et al. (2012). Association between Parkinson's disease and the HLA-DRB1 locus. Mov. Disord. 27, 1104-1110. doi: 10. 1002/mds. 25035.
3. Annese, V., Herrero, M. T., Di Pentima, M., Gomez, A., Lombardi, L., Ros, C. M., et al. (2015). Metalloproteinase-9 contributes to inflammatory glia activation and nigro-striatal pathway degeneration in both mouse and monkey models of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced Parkinsonism. Brain Struct Funct. 220, 703-727. doi: 10. 1007/s00429-014-0718-8.
4. Barcia, C., de Pablos, V., Bautista-Hernández, V., Sánchez-Bahillo, A., Bernal, I., Fernández-Villalba, E., et al. (2005). Increased plasma levels of TNF-alpha but not of IL1-beta in MPTP-treated monkeys one year after the MPTP administration. Parkinsonism Relat. Disord. 11, 435-439. doi: 10. 1016/j. parkreldis. 2005. 05. 006.
5. Barcia, C., Ros, C. M., Annese, V., Carrillo-de Sauvage, M. A., Ros-Bernal, F., Gómez, A., et al. (2012). ROCK/Cdc42-mediated microglial motility and gliapse formation lead to phagocytosis of degenerating dopaminergic neurons in vivo. Sci. Rep. 2: 809. doi: 10. 1038/srep00809.
6. Barcia, C., Ros, C. M., Annese, V., Gómez, A., Ros-Bernal, F., Aguado-Yera, D., et al. (2011). IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease. Cell Death Dis. 2: e142. doi: 10. 1038/cddis. 2011. 17.
7. Barcia, C., Sánchez Bahillo, A., Fernández-Villalba, E., Bautista, V., Poza Y Poza, M., Fernández-Barreiro, A., et al. (2004). Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia 46, 402-409. doi: 10. 1002/glia. 20015.
8. Bardou, I., Kaercher, R. M., Brothers, H. M., Hopp, S. C., Royer, S., and Wenk, G. L. (2014). Age and duration of inflammatory environment differentially affect the neuroimmune response and catecholaminergic neurons in the midbrain and brainstem. Neurobiol. Aging 35, 1065-1073. doi: 10. 1016/j. neurobiolaging. 2013. 11. 006.
9. Beck, J. A., Poulter, M., Campbell, T. A., Uphill, J. B., Adamson, G., Geddes, J. F., et al. (2004). Somatic and germline mosaicism in sporadic early-onset alzheimer's disease. Hum. Mol. Genet. 13, 1219-1224. doi: 10. 1093/hmg/ddh134.
10. Beck, I. M., Vanden Berghe, W., Vermeulen, L., Bougarne, N., Vander Cruyssen, B., Haegeman, G., et al. (2008). Altered subcellular distribution of MSK1 induced by glucocorticoids contributes to NF-kappaB inhibition. EMBO J. 27, 1682-1693. doi: 10. 1038/emboj. 2008. 95.
11. Bellomo, G., Santambrogio, L., Fiacconi, M., Scarponi, A. M., and Ciuffetti, G. (1991). Plasma profiles of adrenocorticotropic hormone, cortisol, growth hormone and prolactin in patients with untreated Parkinson's disease. J. Neurol. 238, 19-22. doi: 10. 1007/bf00319704.
12. Berg, D., Postuma, R. B., Bloem, B., Chan, P., Dubois, B., Gasser, T., et al. (2014). Time to redefine PD? Introductory statement of the MDS task force on the definition of Parkinson's disease. Mov. Disord. 29, 454-462. doi: 10. 1002/mds. 25844.
13. Bhattacharyya, S., Ratajczak, C. K., Vogt, S. K., Kelley, C., Colonna, M., Schreiber, R. D., et al. (2010). TAK1 targeting by glucocorticoids determines JNK and IkappaB regulation in toll-like receptor-stimulated macrophages. Blood 115, 1921-1931. doi: 10. 1182/blood-2009-06-224782.
14. Block, M. L., Zecca, L., and Hong, J. S. (2007). Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 8, 57-69. doi: 10. 1038/nrn2038.
15. Braak, H., Müller, C. M., Rüb, U., Ackermann, H., Bratzke, H., de Vos, R. A., et al. (2006). Pathology associated with sporadic Parkinson's disease-where does it end? J. Neural Transm. Suppl. 70, 89-97. doi: 10. 1007/978-3-211-45295-0_15.
16. Braak, H., Rüb, U., Gai, W. P., and Del Tredici, K. (2003). Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural Transm. 110, 517-536. doi: 10. 1007/s00702-002-0808-2.
17. Buchman, A. S., Shulman, J. M., Nag, S., Leurgans, S. E., Arnold, S. E., Morris, M. C., et al. (2012). Nigral pathology and parkinsonian signs in elders without Parkinson disease. Ann. Neurol. 71, 258-266. doi: 10. 1002/ana. 22588.
18. Cabezas, R., Avila, M., Gonzalez, J., El-Bachá, R. S., Báez, E., García-Segura, L. M., et al. (2014). Astrocytic modulation of blood brain barrier: perspectives on Parkinson's disease. Front. Cell. Neurosci. 4: 211. doi: 10. 3389/fncel. 2014. 00211.
19. Cappellano, G., Carecchio, M., Fleetwood, T., Magistrelli, L., Cantello, R., Dianzani, U., et al. (2013). Immunity and inflammation in neurodegenerative diseases. Am. J. Neurodegener. Dis. 2, 89-107.
20. Carrillo-de Sauvage, M. A., Maatouk, L., Arnoux, I., Pasco, M., Sanz Diez, A., Delahaye, M., et al. (2013). Potent and multiple regulatory actions of microglial glucocorticoid receptors during CNS inflammation. Cell Death Differ. 20, 1546-1557. doi: 10. 1038/cdd. 2013. 108.
21. Castaño, A., Herrera, A. J., Cano, J., and Machado, A. (2002). The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. J. Neurochem. 81, 150-157. doi: 10. 1046/j. 1471-4159. 2002. 00799. x.
22. Chao, Y., Wong, S. C., and Tan, E. K. (2014). Evidence of inflammatory system involvement in Parkinson's disease. Biomed. Res. Int. 2014: 308654. doi: 10. 1155/2014/308654.
23. Charlett, A., Dobbs, R. J., Purkiss, A. G., Wright, D. J., Peterson, D. W., Weller, C., et al. (1998). Cortisol is higher in parkinsonism and associated with gait deficit. Acta Neurol. Scand. 97, 77-85. doi: 10. 1111/j. 1600-0404. 1998. tb00614. x.
24. Chinenov, Y., Gupte, R., and Rogatsky, I. (2013). Nuclear receptors in inflammation control: repression by GR and beyond. Mol. Cell. Endocrinol. 380, 55-64. doi: 10. 1016/j. mce. 2013. 04. 006.
25. Chung, S. J., Armasu, S. M., Biernacka, J. M., Anderson, K. J., Lesnick, T. G., Rider, D. N., et al. (2012). Genomic determinants of motor and cognitive outcomes in Parkinson's disease. Parkinsonism Relat. Disord. 18, 881-886. doi: 10. 1016/j. parkreldis. 2012. 04. 025.
26. Clarimón, J., and Kulisevsky, J. (2013). Parkinson's disease: from genetics to clinical practice. Curr. Genomics 14, 560-567. doi: 10. 2174/1389202914666131210212305.
27. Collier, T. J., Kanaan, N. M., and Kordower, J. H. (2011). Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat. Rev. Neurosci. 12, 359-366. doi: 10. 1038/nrn3039.
28. De Bosscher, K., Vanden Berghe, W., and Haegeman, G. (2003). The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr. Rev. 24, 488-522. doi: 10. 1210/er. 2002-0006.
29. Dejager, L., Vandevyver, S., Petta, I., and Libert, C. (2014). Dominance of the strongest: inflammatory cytokines versus glucocorticoids. Cytokine Growth Factor Rev. 25, 21-33. doi: 10. 1016/j. cytogfr. 2013. 12. 006.
30. Depienne, C., Fedirko, E., Faucheux, J. M., Forlani, S., Bricka, B., Goizet, C., et al. (2007). A de novo SPAST mutation leading to somatic mosaicism is associated with a later age at onset in HSP. Neurogenetics 8, 231-233. doi: 10. 1007/s10048-007-0090-4.
31. Devos, D., Lebouvier, T., Lardeux, B., Biraud, M., Rouaud, T., Pouclet, H., et al. (2013). Colonic inflammation in Parkinson's disease. Neurobiol. Dis. 50, 42-48. doi: 10. 1016/j. nbd. 2012. 09. 007.
32. Dhabhar, F. S. (2002). Stress-induced augmentation of immune function-the role of stress hormones, leukocyte trafficking and cytokines. Brain Behav. Immun. 16, 785-798. doi: 10. 1016/s0889-1591(02)00036-3.
33. Diamond, M. I., Miner, J. N., Yoshinaga, S. K., and Yamamoto, K. R. (1990). Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. Science 249, 1266-1272. doi: 10. 1126/science. 2119054.
34. Djamshidian, A., O'Sullivan, S. S., Papadopoulos, A., Bassett, P., Shaw, K., Averbeck, B. B., et al. (2011). Salivary cortisol levels in Parkinson's disease and its correlation to risk behaviour. J. Neurol. Neurosurg Psychiatry 82, 1107-1111. doi: 10. 1136/jnnp. 2011. 245746.
35. Dobbs, R. J., Charlett, A., Purkiss, A. G., Dobbs, S. M., Weller, C., and Peterson, D. W. (1999). Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol. Scand. 100, 34-41. doi: 10. 1111/j. 1600-0404. 1999. tb00721. x.
36. Dostert, A., and Heinzel, T. (2004). Negative glucocorticoid receptor response elements and their role in glucocorticoid action. Curr. Pharm. Des. 10, 2807-2816. doi: 10. 2174/1381612043383601.
37. Dzamko, N., Geczy, C. L., and Halliday, G. M. (2014). Inflammation is genetically implicated in Parkinson's disease. Neuroscience doi: 10. 1016/j. neuroscience. 2014. 10. 028. [Epub ahead of print].
38. Elbaz, A., Levecque, C., Clavel, J., Vidal, J. S., Richard, F., Amouyel, P., et al. (2004). CYP2D6 polymorphism, pesticide exposure and Parkinson's disease. Ann. Neurol. 55, 430-434. doi: 10. 1002/ana. 20051.
39. Ericsson, A., Kovács, K. J., and Sawchenko, P. E. (1994). A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons. J. Neurosci. 14, 897-913.
40. Forsyth, C. B., Shannon, K. M., Kordower, J. H., Voigt, R. M., Shaikh, M., Jaglin, J. A., et al. (2011). Increased intestinal permeability correlateswith sigmoidmucosa alpha-synuclein staining and endotoxin exposuremarkers in early Parkinson's disease. PLoS One 6: e28032. doi: 10. 1371/journal. pone. 0028032.
41. Galon, J., Franchimont, D., Hiroi, N., Frey, G., Boettner, A., Ehrhart-Bornstein, M., et al. (2002). Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J. 16, 61-71. doi: 10. 1096/fj. 01-0245com.
42. Ghosh, A., Roy, A., Liu, X., Kordower, J. H., Mufson, E. J., Hartley, D. M., et al. (2007). Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U S A 104, 18754-18759. doi: 10. 1073/pnas. 0704908104.
43. Gillardon, F., Schmid, R., and Draheim, H. (2012). Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience208, 41-48. doi: 10. 1016/j. neuroscience. 2012. 02. 001.
44. Goedert, M., Spillantini, M. G., Del Tredici, K., and Braak, H. (2013). 100 years of Lewy pathology. Nat. Rev. Neurol. 9, 13-24. doi: 10. 1038/nrneurol. 2012. 242.
45. Goldman, J. G., and Postuma, R. (2014). Premotor and nonmotor features of Parkinson's disease. Curr. Opin. Neurol. 27, 434-441. doi: 10. 1097/WCO. 0000000000000112.
46. Goujon, E., Parnet, P., Layé, S., Combe, C., and Dantzer, R. (1996). Adrenalectomy enhances pro-inflammatory cytokines gene expression, in the spleen, pituitary and brain of mice in response to lipopolysaccharide. Brain Res. Mol. Brain Res. 36, 53-62. doi: 10. 1016/0169-328x(95)00242-k.
47. Grad, I., and Picard, D. (2007). The glucocorticoid responses are shaped by molecular chaperones. Mol. Cell. Endocrinol. 275, 2-12. doi: 10. 1016/j. mce. 2007. 05. 018.
48. Groeneweg, F. L., Karst, H., de Kloet, E. R., and Joëls, M. (2011). Rapid non-genomic effects of corticosteroids and their role in the central stress response. J. Endocrinol. 209, 153-167. doi: 10. 1530/JOE-10-0472.
49. Halliday, G. M., and Stevens, C. H. (2011). Glia: initiators and progressors of pathology in Parkinson's disease. Mov. Disord. 26, 6-17. doi: 10. 1002/mds. 23455.
50. Harms, A. S., Cao, S., Rowse, A. L., Thome, A. D., Li, X., Mangieri, L. R., et al. (2013). MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation and dopaminergic neurodegeneration. J. Neurosci. 33, 9592-9600. doi: 10. 1523/JNEUROSCI. 5610-12. 2013.
51. Hartmann, A., Veldhuis, J. D., Deuschle, M., Standhardt, H., and Heuser, I. (1997). Twenty-four hour cortisol release profiles in patients with Alzheimer's and Parkinson's disease compared to normal controls: ultradian secretory pulsatility and diurnal variation. Neurobiol. Aging 18, 285-289. doi: 10. 1016/s0197-4580(97)80309-0.
52. Hawkes, C. H., Del Tredici, K., and Braak, H. (2009). Parkinson's disease: the dual hit theory revisited. Ann. N Y Acad. Sci. 1170, 615-622. doi: 10. 1111/j. 1749-6632. 2009. 04365. x.
53. Hellman, L., Nakada, F., Curti, J., Weitzman, E. D., Kream, J., Roffwarg, H., et al. (1970). Cortisol is secreted episodically by normal man. J. Clin. Endocrinol. Metab. 30, 411-422. doi: 10. 1210/jcem-30-4-411.
54. Hench, P. S., Kendall, E. C., Slocumb, C. H., and Polley, H. F. (1950). Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions. Arch. Intern. Med. (Chic). 85, 545-666. doi: 10. 1001/archinte. 1950. 00230100002001.
55. Hill-Burns, E. M., Factor, S. A., Zabetian, C. P., Thomson, G., and Payami, H. (2011). Evidence for more than one Parkinson's disease-associated variant within the HLA region. PLoS One 6: e27109. doi: 10. 1371/journal. pone. 0027109.
56. Huang, C. W., Lui, C. C., Chang, W. N., Lu, C. H., Wang, Y. L., and Chang, C. C. (2009). Elevated basal cortisol level predicts lower hippocampal volume and cognitive decline in Alzheimer's disease. J. Clin. Neurosci. 16, 1283-1286. doi: 10. 1016/j. jocn. 2008. 12. 026.
57. Hunot, S., Boissière, F., Faucheux, B., Brugg, B., Mouatt-Prigent, A., Agid, Y., et al. (1996). Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72, 355-363. doi: 10. 1016/0306-4522(95)00578-1.
58. Iannaccone, S., Cerami, C., Alessio, M., Garibotto, V., Panzacchi, A., Olivieri, S., et al. (2013). In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease. Parkinsonism Relat. Disord. 19, 47-52. doi: 10. 1016/j. parkreldis. 2012. 07. 002.
59. Ito, K., Yamamura, S., Essilfie-Quaye, S., Cosio, B., Ito, M., Barnes, P. J., et al. (2006). Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J. Exp. Med. 203, 7-13. doi: 10. 1084/jem. 20050466.
60. Jackson-Lewis, V., and Smeyne, R. J. (2005). MPTP and SNpc DA neuronal vulnerability: role of dopamine, superoxide and nitric oxide in neurotoxicity. Minireview. Neurotox. Res. 7, 193-201. doi: 10. 1007/bf03036449.
61. Jang, H., Boltz, D., Sturm-Ramirez, K., Shepherd, K. R., Jiao, Y., Webster, R., et al. (2009). Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc. Natl. Acad. Sci. U S A106, 14063-14068. doi: 10. 1073/pnas. 0900096106.
62. Kanaan, N. M., Kordower, J. H., and Collier, T. J. (2008). Age and region-specific responses of microglia, but not astrocytes, suggest a role in selective vulnerability of dopamine neurons after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine exposure in monkeys. Glia 56, 1199-1214. doi: 10. 1002/glia. 20690.
63. Kanaan, N. M., Kordower, J. H., and Collier, T. J. (2010). Age-related changes in glial cells of dopamine midbrain subregions in rhesus monkeys. Neurobiol. Aging 31, 937-952. doi: 10. 1016/j. neurobiolaging. 2008. 07. 006.
64. Kang, Y. M., Zhang, Z. H., Johnson, R. F., Yu, Y., Beltz, T., Johnson, A. K., et al. (2006). Novel effect of mineralocorticoid receptor antagonism to reduce proinflammatory cytokines and hypothalamic activation in rats with ischemia-induced heart failure. Circ. Res. 99, 758-766. doi: 10. 1161/01. res. 0000244092. 95152. 86.
65. Karin, M., and Greten, F. R. (2005). NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5, 749-759. doi: 10. 1038/nri1703.
66. Kawai, T., and Akira, S. (2010). The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat. Immunol. 11, 373-384. doi: 10. 1038/ni. 1863.
67. Kieburtz, K., and Wunderle, K. B. (2013). Parkinson's disease: evidence for environmental risk factors. Mov. Disord. 28, 8-13. doi: 10. 1002/mds. 25150.
68. Kim, H. J., and Jeon, B. S. (2014). Hypothesis: somatic mosaicism and parkinson disease. Exp. Neurobiol. 23, 271-276. doi: 10. 5607/en. 2014. 23. 4. 271.
69. Kino, T., Manoli, I., Kelkar, S., Wang, Y., Su, Y. A., and Chrousos, G. P. (2009). Glucocorticoid receptor (GR) beta has intrinsic, GRalpha-independent transcriptional activity. Biochem. Biophys. Res. Commun. 381, 671-675. doi: 10. 1016/j. bbrc. 2009. 02. 110.
70. Kurkowska-Jastrzebska, I., Litwin, T., Joniec, I., Ciesielska, A., Przybyłkowski, A., Członkowski, A., et al. (2004). Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. Int. Immunopharmacol. 4, 1307-1318. doi: 10. 1016/j. intimp. 2004. 05. 006.
71. Lill, C. M., Roehr, J. T., McQueen, M. B., Kavvoura, F. K., Bagade, S., Schjeide, B. M., et al. (2012). Comprehensive research synopsis and systematic metaanalyses in Parkinson's disease genetics: the PDGene database. PLoS Genet. 8: e1002548. doi: 10. 1371/journal. pgen. 1002548.
72. Liu, M., and Bing, G. (2011). Lipopolysaccaride animal models for Parkinson's disease. Parkinson Dis. 2011: 327089. doi: 10. 4061/2011/327089.
73. Liu, X., Cheng, R., Verbitsky, M., Kisselev, S., Browne, A., Mejia-Sanatana, H., et al. (2011). Genome-wide association study identifies candidate genes for Parkinson's disease in an Ashkenazi Jewish population. BMC Med. Genet. 12: 104. doi: 10. 1186/1471-2350-12-104.
74. Maetzler, W., Apel, A., Langkamp, M., Deuschle, C., Dilger, S. S., Stirnkorb, J. G., et al. (2014). Comparable autoantibody serum levels against amyloid-and inflammation-associated proteins in Parkinson's disease patients and controls. PLoS One 9: e88604. doi: 10. 1371/journal. pone. 0088604.
75. Matsubara, T., Funato, H., Kobayashi, A., Nobumoto, M., and Watanabe, Y. (2006). Reduced Glucocorticoid receptor alpha expression in mood disorder patients and first-degree relatives. Biol. Psychiatry 59, 689-695. doi: 10. 1016/j. biopsych. 2005. 09. 026.
76. McEwen, B. S. (2007). Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol. Rev. 87, 873-904. doi: 10. 1152/physrev. 00041. 2006.
77. McGeer, P. L., and McGeer, E. G. (2008). The alpha-synuclein burden hypothesis of Parkinson disease and its relationship to Alzheimer disease. Exp. Neurol. 212, 235-238. doi: 10. 1016/j. expneurol. 2008. 04. 008.
78. Moehle, M. S., Webber, P. J., Tse, T., Sukar, N., Standaert, D. G., DeSilva, T. M., et al. (2012). LRRK2 inhibition attenuates microglial inflammatory responses. J. Neurosci. 32, 1602-1611. doi: 10. 1523/JNEUROSCI. 5601-11. 2012.
79. Mogi, M., Harada, M., Kondo, T., Riederer, P., Inagaki, H., Minami, M., et al. (1994). Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180, 147-150. doi: 10. 1016/0304-3940(94)90508-8.
80. Monahan, A. J., Warren, M., and Carvey, P. M. (2008). Neuroinflammation and peripheral immune infiltration in Parkinson's disease: an autoimmune hypothesis. Cell Transplant. 17, 363-372. doi: 10. 3727/096368908784423328.
81. Müller, T., Welnic, J., and Muhlack, S. (2007). Acute levodopa administration reduces cortisol release in patients with Parkinson's disease. J. Neural Transm. 114, 347-350. doi: 10. 1007/s00702-006-0552-0.
82. Nadeau, S., and Rivest, S. (2002). Endotoxemia prevents the cerebral inflammatory wave induced by intraparenchymal lipopolysaccharide injection: role of glucocorticoids and CD14. J. Immunol. 169, 3370-3381. doi: 10. 4049/jimmunol. 169. 6. 3370.
83. Nadeau, S., and Rivest, S. (2003). Glucocorticoids play a fundamental role in protecting the brain during innate immune response. J. Neurosci. 23, 5536-5544.
84. Nalls, M. A., Bras, J., Hernandez, D. G., Keller, M. F., Majounie, E., Renton, A. E., et al. (2015). NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. Neurobiol. Aging 36, 1605. e7-1605. e12. doi: 10. 1016/j. neurobiolaging. 2014. 07. 028.
85. Nalls, M. A., Pankratz, N., Lill, C. M., Do, C. B., Hernandez, D. G., Saad, M., et al. (2014). Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat. Genet. 46, 989-993. doi: 10. 1038/ng. 3043.
86. Noh, H., Jeon, J., and Seo, H. (2014). Systemic injection of LPS induces region-specific neuroinflammation and mitochondrial dysfunction in normal mouse brain. Neurochem. Int. 69, 35-40. doi: 10. 1016/j. neuint. 2014. 02. 008.
87. Oakley, R. H., and Cidlowski, J. A. (2013). The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease. J. Allergy Clin. Immunol. 132, 1033-1044. doi: 10. 1016/j. jaci. 2013. 09. 007.
88. O'Connor, K. A., Johnson, J. D., Hansen, M. K., Wieseler Frank, J. L., Maksimova, E., Watkins, L. R., et al. (2003). Peripheral and central proinflammatory cytokine response to a severe acute stressor. Brain Res. 991, 123-132. doi: 10. 1016/j. brainres. 2003. 08. 006.
89. Orr, C. F., Rowe, D. B., Mizuno, Y., Mori, H., and Halliday, G. M. (2005). A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 128(Pt. 11), 2665-2674. doi: 10. 1093/brain/awh625.
90. Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., et al. (2005). Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 57, 168-175. doi: 10. 1002/ana. 20338.
91. Perlman, W. R., Webster, M. J., Kleinman, J. E., and Weickert, C. S. (2004). Reduced glucocorticoid and estrogen receptor alpha messenger ribonucleic acid levels in the amygdala of patients with major mental illness. Biol. Psychiatry 56, 844-852. doi: 10. 1016/j. biopsych. 2004. 09. 006.
92. Pieper, H. C., Evert, B. O., Kaut, O., Riederer, P. F., Waha, A., and Wüllner, U. (2008). Different methylation of the TNF-alpha promoter in cortex and substantia nigra: implications for selective neuronal vulnerability. Neurobiol. Dis. 32, 521-527. doi: 10. 1016/j. nbd. 2008. 09. 010.
93. Pihlstrøm, L., Axelsson, G., Bjørnarå, K. A., Dizdar, N., Fardell, C., Forsgren, L., et al. (2013). Supportive evidence for 11 loci from genome-wide association studies in Parkinson's disease. Neurobiol. Aging 34, 1708. e7-1708. e13. doi: 10. 1016/j. neurobiolaging. 2012. 10. 019.
94. Portela, A., and Esteller, M. (2010). Epigenetic modifications and human disease. Nat. Biotechnol. 28, 1057-1068. doi: 10. 1038/nbt. 1685.
95. Pott Godoy, M. C., Tarelli, R., Ferrari, C. C., Sarchi, M. I., and Pitossi, F. J. (2008). Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain 131(Pt. 7), 1880-1894. doi: 10. 1093/brain/awn101.
96. Pringsheim, T., Jette, N., Frolkis, A., and Steeves, T. D. (2014). The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov. Disord. 29, 1583-1590. doi: 10. 1002/mds. 25945.
97. Proukakis, C., Shoaee, M., Morris, J., Brier, T., Kara, E., Sheerin, U. M., et al. (2014). Analysis of Parkinson's disease brain-derived DNA for alpha-synuclein coding somatic mutations. Mov. Disord. 29, 1060-1064. doi: 10. 1002/mds. 25883.
98. Ravenholt, R. T., and Foege, W. H. (1982). 1918 influenza, encephalitis lethargica, parkinsonism. Lancet 2, 860-864. doi: 10. 1016/s0140-6736(82)90820-0.
99. Reale, M., Greig, N. H., and Kamal, M. A. (2009a). Peripheral chemo-cytokine profiles in Alzheimer's and Parkinson's diseases. Mini. Rev. Med. Chem. 9, 1229-1241. doi: 10. 2174/138955709789055199.
100. Reale, M., Iarlori, C., Thomas, A., Gambi, D., Perfetti, B., Di Nicola, M., et al. (2009b). Peripheral cytokines profile in Parkinson's disease. Brain Behav. Immun. 23, 55-63. doi: 10. 1016/j. bbi. 2008. 07. 003.
101. Rees, K., Stowe, R., Patel, S., Ives, N., Breen, K., Clarke, C. E., et al. (2011). Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies. Cochrane Database Syst. Rev. 9: CD008454. doi: 10. 1002/14651858. CD008454.
102. Reichstein, T. (1951). Chemistry of adrenal cortex hormones. Bull. Schweiz. Akad. Med. Wiss. 7, 359-370.
103. Ros-Bernal, F., Hunot, S., Herrero, M. T., Parnadeau, S., Corvol, J. C., Lu, L., et al. (2011). Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. Proc. Natl. Acad. Sci. U S A 108, 6632-6637. doi: 10. 1073/pnas. 1017820108.
104. Rosenfeld, M. G., and Glass, C. K. (2001). Coregulator codes of transcriptional regulation by nuclear receptors. J. Biol. Chem. 276, 36865-36868. doi: 10. 1074/jbc. r100041200.
105. Russo, I., Bubacco, L., and Greggio, E. (2014). LRRK2 and neuroinflammation: partners in crime in Parkinson's disease?. J. Neuroinflammation 11: 52. doi: 10. 1186/1742-2094-11-52.
106. Saijo, K., Winner, B., Carson, C. T., Collier, J. G., Boyer, L., Rosenfeld, M. G., et al. (2009). A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 137, 47-59. doi: 10. 1016/j. cell. 2009. 01. 038.
107. Serrats, J., Schiltz, J. C., García-Bueno, B., van Rooijen, N., Reyes, T. M., and Sawchenko, P. E. (2010). Dual roles for perivascular macrophages in immune-to-brain signaling. Neuron 65, 94-106. doi: 10. 1016/j. neuron. 2009. 11. 032.
108. Sharkey, K. A., and Savidge, T. C. (2014). Role of enteric neurotransmission in host defense and protection of the gastrointestinal tract. Auton. Neurosci. 181, 94-106. doi: 10. 1016/j. autneu. 2013. 12. 006.
109. Sierra, A., Gottfried-Blackmore, A., Milner, T. A., McEwen, B. S., and Bulloch, K. (2008). Steroid hormone receptor expression and function in microglia. Glia 56, 659-674. doi: 10. 1002/glia. 20644.
110. Sorrells, A. D., Eicher, S. D., Harris, M. J., Pajor, E. A., and Richert, B. T. (2007). Periparturient cortisol, acute phase cytokine and acute phase protein profiles of gilts housed in groups or stalls during gestation. J. Anim. Sci. 85, 1750-1757. doi: 10. 2527/jas. 2007-0025.
111. Spillantini, M., Schmidt, M., Lee, V., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997). Alpha-synuclein in Lewy bodies. Nature 388, 839-840. doi: 10. 1038/42166.
112. Stolp, H. B., and Dziegielewska, K. M. (2009). Review: role of developmental inflammation and blood-brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases. Neuropathol. Appl. Neurobiol. 35, 132-146. doi: 10. 1111/j. 1365-2990. 2008. 01005. x.
113. Stypula, G., Kunert-Radek, J., Stepień, H., Zylińska, K., and Pawlikowski, M. (1996). Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with parkinson's disease. Neuroimmunomodulation 3, 131-134. doi: 10. 1159/000097237.
114. Su, X., and Federoff, J. H. (2014). Immune responses in Parkinson's disease: interplay between central and peripheral immune systems. Biomed. Res. Int. 2014: 275178. doi: 10. 1155/2014/275178.
115. Sugama, S., Takenouchi, T., Kitani, H., Fujita, M., and Hashimoto, M. (2009). Microglial activation is inhibited by corticosterone in dopaminergic neurodegeneration. J. Neuroimmunol. 208, 104-114. doi: 10. 1016/j. jneuroim. 2009. 01. 016.
116. Surjit, M., Ganti, K. P., Mukherji, A., Ye, T., Hua, G., Metzger, D., et al. (2011). Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor. Cell 145, 224-241. doi: 10. 1016/j. cell. 2011. 03. 027.
117. Tang, P., Chong, L., Li, X., Liu, Y., Liu, P., Hou, C., et al. (2014). Correlation between serum RANTES levels and the severity of Parkinson's disease. Oxid. Med. Cell. Longev. 2014: 208408. doi: 10. 1155/2014/208408.
118. Topçu, M., Akyerli, C., Sayi, A., Törüner, G. A., Koçoğlu, S. R., Climbis, M., et al. (2002). Somatic mosaicism for a MECP2 mutation associated with classic Rett syndrome in a boy. Eur. J. Hum. Genet. 10, 77-81. doi: 10. 1038/sj. ejhg. 5200745.
119. Veldhuis, J. D., Iranmanesh, A., Lizarralde, G., and Johnson, M. L. (1989). Amplitude modulation of a burstlike mode of cortisol secretion subserves the circadian glucocorticoid rhythm. Am. J. Physiol. 257, E6-E14.
120. Wahner, A. D., Sinsheimer, J. S., Bronstein, J. M., and Ritz, B. (2007). Inflammatory cytokine gene polymorphisms and increased risk of Parkinson disease. Neurology 64, 836-840. doi: 10. 1001/archneur. 64. 6. 836.
121. Wakabayashi, K., and Takahashi, H. (1997). Neuropathology of autonomic nervous system in Parkinson's disease. Eur. Neurol. 38(Suppl. 2), 2-7. doi: 10. 1159/000113469.
122. Wilms, H., Zecca, L., Rosenstiel, P., Sievers, J., Deuschl, G., and Lucius, R. (2007). Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications. Curr. Pharm. Des. 13, 1925-1928. doi: 10. 2174/138161207780858429.
123. Wissemann, W. T., Hill-Burns, E. M., Zabetian, C. P., Factor, S. A., Patsopoulos, N., Hoglund, B., et al. (2013). Association of Parkinson disease with structural and regulatory variants in the HLA region. Am. J. Hum. Genet. 93, 984-993. doi: 10. 1016/j. ajhg. 2013. 10. 009.
124. Young, E. A., Abelson, J., and Lightman, S. L. (2004). Cortisol pulsatility and its role in stress regulation and health. Front. Neuroendocrinol. 25, 69-76. doi: 10. 1016/j. yfrne. 2004. 07. 001.
125. Zarković, M., Ignjatović, S., Dajak, M., Cirić, J., Beleslin, B., Savić, S., et al. (2008). Cortisol response to ACTH stimulation correlates with blood interleukin 6 concentration in healthy humans. Eur. J. Endocrinol. 159, 649-652. doi: 10. 1530/EJE-08-0544.
126. Zhou, J., and Cidlowski, J. A. (2005). The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. Steroids 70, 407-417. doi: 10. 1016/j. steroids. 2005. 02. 006.